Semaglutide

Semaglutide is a GLP-1 receptor agonist originally developed for type 2 diabetes (Ozempic) and subsequently approved for chronic weight management (Wegovy). Compounded semaglutide is widely prescribed in clinical practice for weight loss programs. It is one of the highest-demand compounded medications in the US and represents a core revenue driver for practices offering medical weight management.

Category
Weight Loss & Metabolic
Demand
High
Route
Subcutaneous injection
FDA status
Compounding eligibility tied to FDA drug shortage status; verify current classification before prescribing
Also known as
Compounded SemaglutideGLP-1 AgonistOzempic/Wegovy (brand references)

How Semaglutide Works

Semaglutide is a modified GLP-1 analog with 94% homology to native GLP-1, engineered with a C-18 fatty acid chain that enables albumin binding and extends half-life to approximately 7 days. It activates GLP-1 receptors in the hypothalamus to reduce appetite, in the pancreas to enhance glucose-dependent insulin secretion, and in the GI tract to delay gastric emptying [1]. The net effect is sustained caloric reduction, improved glycemic control, and progressive weight loss.

Clinical Evidence

The STEP 1 trial demonstrated 14.9% mean body weight reduction at 68 weeks with semaglutide 2.4mg weekly versus 2.4% with placebo [2]. The SELECT cardiovascular outcomes trial showed a 20% reduction in major adverse cardiovascular events in overweight/obese patients without diabetes [3]. Semaglutide received FDA approval for chronic weight management (Wegovy) in June 2021 based on this evidence [1]. Real-world data from clinical practice settings confirms similar efficacy when combined with lifestyle modification programs.

Clinical Uses

  • Chronic weight management in patients with BMI >= 30 or >= 27 with comorbidities
  • Type 2 diabetes management (glycemic control)
  • Cardiovascular risk reduction in obese patients
  • Metabolic syndrome management
  • Appetite suppression and caloric reduction support

Patient Selection and Screening

Ideal candidates have BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea) [1]. Screen for personal or family history of medullary thyroid carcinoma or MEN 2 syndrome (absolute contraindication). Evaluate for history of pancreatitis, gallbladder disease, and eating disorders before initiation. Patients should understand this is a long-term therapy with potential for weight regain upon discontinuation [2].

Dosing and Administration

Standard titration per FDA labeling: 0.25mg weekly for 4 weeks, then 0.5mg for 4 weeks, then 1.0mg for 4 weeks, then 1.7mg for 4 weeks, then 2.4mg maintenance [1]. Compounded versions may use different concentrations; adjust volume accordingly [4]. Some clinicians use slower titration (6-8 week intervals) for patients with significant GI sensitivity. Treatment duration is indefinite for weight maintenance; clinical judgment should guide discontinuation planning.

Route
Subcutaneous injection
Protocol notes
Administered via weekly subcutaneous injection with dose titration over 4-8 weeks to minimize GI side effects. Starting dose is typically 0.25mg weekly, titrated to maintenance dose.

Safety and Monitoring

Potential side effects

  • Nausea (40-44% incidence, typically improves with continued use)
  • Diarrhea, vomiting, and constipation (common during dose escalation)
  • Injection site reactions (erythema, pruritus)
  • Pancreatitis (rare but serious; discontinue if suspected)
  • Gallbladder events including cholelithiasis (monitor in rapid weight loss)

Clinical considerations

  • Requires dose titration to minimize gastrointestinal side effects (nausea, vomiting, diarrhea)
  • Contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2
  • Monitor for pancreatitis symptoms; discontinue if suspected
  • Screen for history of eating disorders before prescribing
  • FDA shortage status affects compounding eligibility; verify current status

Practice Economics

Semaglutide weight loss programs represent the highest-revenue peptide offering for most practices, with monthly patient spend ranging from $300-600 for compounded formulations [4]. Programs structured with intake labs, monthly follow-ups, and dietary counseling can generate $3,000-6,000 per patient annually. Market demand remains exceptionally high, making this a primary patient acquisition driver.

FDA Category Status

Compounding eligibility tied to FDA drug shortage status; verify current classification before prescribing

FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify current status before prescribing.

Frequently Asked Questions

What is the difference between branded and compounded semaglutide?

Branded semaglutide (Ozempic, Wegovy) is manufactured by Novo Nordisk. Compounded semaglutide is produced by 503A or 503B compounding pharmacies and is available when the drug is on the FDA shortage list. Both contain the same active ingredient, but compounded versions may differ in formulation, delivery device, and pricing.

How should practices structure semaglutide weight loss programs?

Successful programs typically include initial consultation with labs (A1C, metabolic panel, thyroid), dose titration protocol over 16-20 weeks, monthly or biweekly check-ins, dietary counseling, and a maintenance phase plan. Practices should also plan for supply continuity given the evolving FDA shortage status.

What are the key compliance considerations for prescribing compounded semaglutide?

Physicians must verify current FDA shortage status, use a licensed 503A or 503B pharmacy, document clinical justification, and ensure informed consent covers the difference between branded and compounded formulations. State board rules on compounding oversight vary.

References

  1. FDA Approval of Wegovy (semaglutide 2.4mg) for Chronic Weight Management
  2. Wilding et al. - Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1, NEJM 2021)
  3. Lincoff et al. - Semaglutide and Cardiovascular Outcomes in Obesity (SELECT Trial, NEJM 2023)
  4. FDA Compounding and Drug Shortage Information

Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable regulations. Always verify FDA category status and compounding eligibility before prescribing.

Launch a Peptide Program With Karpa

Karpa handles intake, licensed prescribing, and direct-to-patient pharmacy fulfillment across all 50 states. No medical license required.

Explore peptide programs